COVID-19 and lymphangioleiomyomatosis: Experience at a reference center and the potential impact of the use of mTOR inhibitors.
作者信息
Baldi Bruno Guedes, Amaral Alexandre Franco, de Figueiredo Braga Colares Phillipe, Kairalla Ronaldo Adib, de Oliveira Martina Rodrigues, Carvalho Carlos Roberto Ribeiro
机构信息
Divisão de Pneumologia, Instituto do Coração (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
出版信息
Am J Med Genet A. 2020 Dec;182(12):3068-3070. doi: 10.1002/ajmg.a.61877. Epub 2020 Sep 18.
Abstract
摘要
相似文献
1
COVID-19 and lymphangioleiomyomatosis: Experience at a reference center and the potential impact of the use of mTOR inhibitors.
Am J Med Genet A. 2020 Dec;182(12):3068-3070. doi: 10.1002/ajmg.a.61877. Epub 2020 Sep 18.
2
mTOR signaling in lymphangioleiomyomatosis.
Lymphat Res Biol. 2010 Mar;8(1):33-42. doi: 10.1089/lrb.2009.0019.
3
mTOR treatment in lymphangioleiomyomatosis: the role of everolimus.
Expert Rev Respir Med. 2016;10(3):249-60. doi: 10.1586/17476348.2016.1148603.
4
Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
Expert Rev Respir Med. 2014 Dec;8(6):657-60. doi: 10.1586/17476348.2014.956728. Epub 2014 Sep 9.
5
The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis.
Orphanet J Rare Dis. 2018 Aug 14;13(1):134. doi: 10.1186/s13023-018-0874-7.
6
Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre.
Lung. 2017 Dec;195(6):699-705. doi: 10.1007/s00408-017-0045-y. Epub 2017 Aug 19.
7
Lymphangioleiomyomatosis: New Treatment Perspectives.
Lung. 2015 Aug;193(4):467-75. doi: 10.1007/s00408-015-9742-6. Epub 2015 May 17.
8
Pulmonary lymphangioleiomyomatosis: A proposed state of neoplastic senescence.
Med Hypotheses. 2019 Nov;132:109372. doi: 10.1016/j.mehy.2019.109372. Epub 2019 Aug 21.
9
Immunohistological features related to functional impairment in lymphangioleiomyomatosis.
Respir Res. 2018 May 8;19(1):83. doi: 10.1186/s12931-018-0797-9.
10
Treatment of lymphangioleiomyomatosis and Camões.
J Bras Pneumol. 2015 Jul-Aug;41(4):295-6. doi: 10.1590/S1806-37132015000400001.
引用本文的文献
1
Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study.
Orphanet J Rare Dis. 2024 Jul 3;19(1):247. doi: 10.1186/s13023-024-03260-4.
2
Acute Hypoxemic Respiratory Failure Due to COVID-19 in a Patient With Underlying Lymphangioleiomyomatosis.
Cureus. 2022 Jun 12;14(6):e25871. doi: 10.7759/cureus.25871. eCollection 2022 Jun.
3
Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement.
Ital J Pediatr. 2022 Jan 12;48(1):7. doi: 10.1186/s13052-021-01187-1.
4
COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition.
Chest. 2022 Jun;161(6):1589-1593. doi: 10.1016/j.chest.2021.12.640. Epub 2021 Dec 21.
5
A 34-Year-Old Woman from Brazil with Pulmonary Lymphangioleiomyomatosis Diagnosed by Raised Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels and Lung Cysts on Computed Tomography Imaging Presenting with COVID-19 Pneumonia.
Am J Case Rep. 2021 Jul 31;22:e932660. doi: 10.12659/AJCR.932660.
6
Stick or twist: Everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic.
Seizure. 2021 Oct;91:271-272. doi: 10.1016/j.seizure.2021.06.035. Epub 2021 Jul 5.
7
COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease.
Transl Res. 2021 Jun;232:13-36. doi: 10.1016/j.trsl.2020.12.007. Epub 2020 Dec 19.
本文引用的文献
1
Tuberous sclerosis complex (TSC), lymphangioleiomyomatosis, and COVID-19: The experience of a TSC clinic in Italy.
Am J Med Genet A. 2020 Nov;182(11):2479-2485. doi: 10.1002/ajmg.a.61810. Epub 2020 Aug 17.
2
An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?
Front Pharmacol. 2020 May 29;11:856. doi: 10.3389/fphar.2020.00856. eCollection 2020.
3
Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.
J Med Virol. 2020 Sep;92(9):1495-1500. doi: 10.1002/jmv.26009. Epub 2020 May 22.
4
Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.
Am J Respir Crit Care Med. 2016 Sep 15;194(6):748-61. doi: 10.1164/rccm.201607-1384ST.
5
Lymphangioleiomyomatosis.
Clin Chest Med. 2016 Sep;37(3):389-403. doi: 10.1016/j.ccm.2016.04.002.
Zotero 插件